Skip to content

An investigation study of the glycemic index (GI)

An investigation study of the glycemic index (GI): an open-label trial - An investigation study of the glycemic index (GI)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000039555
Enrollment
10
Registered
2020-02-21
Start date
2020-02-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese subjects

Interventions

Duration: single dose Test food 1: sugar Test food 2: sugar containing sugarcane polyphenol Reference food: Trelan-G 50 g Administration: &lt
After taking blood samples before intake, dissolve test food 1 in water (150 mL) and drink within 15 minutes. &lt
After taking blood samples before intake, dissolve test food 2 in water (150 mL) and drink within 15 minutes. &lt
After taking blood samples before intake, drink reference food within 15 minutes. * The intervention sequence is reference food, reference food, test food 1 to test food 2 and each beverage is sing

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese adult subjects 2. Subjects who are not more than 30 kg/m2 in BMI 3. Subjects who are judged as eligible to participate in the study by the physician

Exclusion criteria

Exclusion criteria: 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who have food allergies and/or food intolerances. Particularly, subjects who have lactose intolerance. 5. Subjects who have abnormal glucose tolerance 6. Subjects who take medications known to affect glucose tolerance 7. Subjects who have used insulin to treat diabetes or taken antihyperglycemic drugs 8. Subjects who are the presence or under the treatment of disease which influence digestion and absorption of nutrients 9. Subjects who are taking steroids, protease inhibitors, or antipsychotics 10. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily 11. Subjects who are currently taking medicines (include herbal medicines) and supplements 12. Subjects who are allergic to medicines and/or the test food related products 13. Subjects who are pregnant, breast-feeding, and planning to become pregnant 14. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 15. Subjects who are judged as ineligible to participate in the study by the physician

Design outcomes

Primary

MeasureTime frame
GI

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026